Baraclude, which is BMY’s only Hepatitis B product, reported revenues of $233.0 million in 4Q17.
For 4Q17, Opdivo reported revenues of ~$1.4 billion for 4.0% growth compared to revenues of ~$1.3 billion during 4Q16.
The oncology portfolio contributes more than 47.0% of total revenues for Bristol-Myers Squibb in 4Q17.
Bristol-Myers Squibb (BMY) beat Wall Street estimates for earnings per share and revenues during 4Q17. BMY reported revenues of $5.5 billion for 4Q17.
Aurora Cannabis (ACBFF) was in the news last week, as it plans to acquire 19.9% ownership in Liquor Stores for a total value of $103.5 million.
On February 5, BC (British Columbia) released its regulatory framework for non-medical cannabis.
In contrast to how broad markets performed last week, cannabis stocks had another good week.
As of February 12, 2018, according to a Reuters survey consisting of 19 investment research firms, 63% of analysts recommended BD as a “buy,” and 37% rate it as a “hold.”
On January 22, 2018, Becton Dickinson (BDX) announced a quarterly dividend of $0.75 per common share for 2Q18.
Becton Dickinson (BDX) announced its fiscal 2018 guidance, which includes the company’s recently acquired Bard business, during the company’s 1Q18 earnings release.
BD posted 1Q18 results as a standalone company and didn’t include Bard sales in 1Q18.
On February 6, 2018, BD released its 1Q18 earnings results, which came in ahead of expectations.
In the US market in 4Q17, Ibrance generated revenues of $777 million, which reflected ~27% growth on a YoY basis.
In 4Q17, Pfizer (PFE) generated revenues of $168 million from the Xtandi alliance which reflected ~21% growth on a year-over-year basis.
In the US and international markets in 4Q17, Sutent generated revenues of $96 million and $180 million, respectively.
In 4Q17, Pfizer’s (PFE) Bosulif generated revenues of $70 million, which reflected ~52% growth on a YoY (year-over-year) basis.
In 4Q17, Pfizer’s Inlyta generated revenues of $83 million, which is a 14% decline YoY and a 1% decline on a quarter-over-quarter basis.
In fiscal 2017, Pfizer’s oncology business generated revenues of $6.06 billion, which reflected ~33% growth on a YoY basis.
Bard recently received PMA approval for its 5French ProSeries LifeStent platform, which was launched in Europe in mid-2017.
Becton, Dickinson and Company (BDX) completed the acquisition of Bard on January 29, 2018.